Intellia Therapeutics (NTLA) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Intellia Therapeutics (NTLA) has outperformed QuidelOrtho (QDEL) over the past year, losing 42.7% versus a loss of 55.6%. Over five years, QDEL leads with a -90.4% price change compared with -91.0% for NTLA. Intellia Therapeutics is the larger company by market cap ($1.77 billion vs $851.0 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTLA | QDEL |
|---|---|---|
| Share price | $12.60 | $12.41 |
| Market cap | $1.77B | $851.02M |
| 1-day change | +7.60% | +0.81% |
| YTD return | +30.26% | -56.90% |
| 1-year return | -42.71% | -55.58% |
| 5-year return | -91.03% | -90.40% |
| Forward P/E | — | 8.61 |
| EPS (TTM) | $-3.35 | $-15.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.25 | $35.58 |
| 52-week low | $7.95 | $9.92 |
| Distance from 52-week high | -55.40% | -65.12% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +83.41% | +18.21% |
| Average volume | 4.16M | 1.49M |
| Shares outstanding | 140.13M | 68.58M |
| Employees | 377 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 2.1 times larger than QuidelOrtho by market value ($1.77B vs $851.02M).
- NTLA has outperformed QDEL by 12.9 percentage points over the past year.
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
NTLA vs QDEL FAQ
Which is bigger, Intellia Therapeutics or QuidelOrtho?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.77B compared with $851.02M for QuidelOrtho (QDEL).
Which stock has performed better over the past year, NTLA or QDEL?
NTLA returned -42.71% over the past 12 months, compared with -55.58% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Intellia Therapeutics and QuidelOrtho in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.